UHS on XNYS, Health Care, Universal Health Services, Inc., job postings
Measures activity, not value. Not investment advice.
Revenue rose 8.0% to $18.4B over 12 months but shares are down 20% in a year.
GoodInstitutional holders rose 8.4% to 630 in the latest quarter
GoodNet income rose 6.3% to $1.5B over 12 months
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Universal Health Services primarily offers healthcare services through its behavioral health centers, acute care hospitals, and related outpatient facilities. As of late 2025, the company operated 346 inpatient behavioral health centers, 29 acute care hospitals, and many supportive outpatient facilities. Its operations are concentrated in the US, particularly in Nevada (21% of 2025 operating profits), Texas (19%), and California (13%), although it does have some exposure to the UK behavioral health market (6% of 2025 sales) too. While its acute care services account for over 55% of revenue, the behavioral health centers sport higher margins and account for over 55% of pretax profits.
Industry
Services-general medical & surgical hospitals, nec (Health Care)
expected around 25 Feb 2027 (an estimate: a year ago it reported on 26 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $4.7B, net income $308.7M.
31 Dec 2021RevenueNet incometallest bar $4.7B30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$4.7B
$308.7M
30 Jun 2026
$4.6B
$358.4M
31 Mar 2026
$4.5B
$348.7M
31 Dec 2025
$4.5B
$445.9M
30 Sep 2025
$4.5B
$373.0M
30 Jun 2025
$4.3B
$353.2M
31 Mar 2025
$4.1B
$316.7M
31 Dec 2024
$4.1B
$332.4M
30 Sep 2024
$4.0B
$258.7M
30 Jun 2024
$3.9B
$289.2M
31 Mar 2024
$3.8B
$261.8M
31 Dec 2023
$3.7B
$216.4M
30 Sep 2023
$3.6B
$167.0M
30 Jun 2023
$3.5B
$171.3M
31 Mar 2023
$3.5B
$163.1M
31 Dec 2022
$3.4B
$174.8M
30 Sep 2022
$3.3B
$182.8M
30 Jun 2022
$3.3B
$164.1M
31 Mar 2022
$3.3B
$153.9M
31 Dec 2021
$3.3B
$239.1M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$18.4B
$17.0B
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+8.0%
+4.0%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$1.5B
$1.4B
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
$23.88
$21.03
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
63.5%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
10.8%
11.5%
-9.1%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
8.0%
8.1%
5.1%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
19.8%
-44.4%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$1.1B
$968.3M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$168.7M
$112.9M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$5.7B
$4.7B
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
$5.5B
$4.6B
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.75
0.06
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
–
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
7.1
7.1
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
0.56
0.75
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
0.87
1.1
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
1.4
2.2
Dividend yieldiDividends per share declared in the latest fiscal year divided by the share price.
0.45%
1.6%
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
–
No data for this company
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+8.4%
630 13F filers vs 581
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
–
No 13F holdings or share count.
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
–
2.5M shares sold short (30 Oct 2026); no share count in the company's filings in our data
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
3.6
2.5M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-3.5%
2.6M shares sold short in the report before, 2.5M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
60%
60% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 66%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+5.3%
$4.7B vs $4.5B (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
-6.1%
$214.9M vs $228.9M (quarter ended 30 Sep 2026)
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$60K
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
51
51 articles in the last 7 days; its usual week has 6 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
8.5×
51 articles in the last 7 days; its usual week has 6.
Price $179.43 on 20 Nov 2026, -20% over 12 months (12-month range $141.17 to $244.18)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $128K in the last 12 months (the 12 months before: -$1.8M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 3 published in the last 12 months (none in the 12 months before).Revenue per quarter. Revenue $4.7B in the latest quarter, +5.3% on a year earlier.Capital spending per quarter. Capital spending $214.9M in the latest quarter, -6.1% on a year earlier.Institutional holders (13F filers). 630 13F filers reported holding it in the latest 13F quarter, +5.0% on a year earlier.Federal obligations. Federal obligations: $0 published in the last 12 months, -100% on the 12 months before.Lobbying spend. Lobbying spend: $60K published in the last 12 months, -25% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.
Quarter ended 31 Dec 2021: $3.3B, +6.1% on a year earlier; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $3.3B, +9.3% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $3.3B, +3.9% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $3.3B, +5.7% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $3.4B, +5.2% on a year earlier; public on 28 Feb 2023
Quarter ended 31 Mar 2023: $3.5B, +5.3% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $3.5B, +6.8% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $3.6B, +6.8% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $3.7B, +7.4% on a year earlier; public on 28 Feb 2024
Quarter ended 31 Mar 2024: $3.8B, +11% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $3.9B, +10% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $4.0B, +11% on a year earlier; public on 9 Nov 2024
Quarter ended 31 Dec 2024: $4.1B, +11% on a year earlier; public on 27 Feb 2025
Quarter ended 31 Mar 2025: $4.1B, +6.7% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $4.3B, +9.6% on a year earlier; public on 9 Aug 2025
Quarter ended 30 Sep 2025: $4.5B, +13% on a year earlier; public on 8 Nov 2025
Quarter ended 31 Dec 2025: $4.5B, +9.1% on a year earlier; public on 26 Feb 2026
Quarter ended 31 Mar 2026: $4.5B, +9.6% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $4.6B, +8.3% on a year earlier; public on 8 Aug 2026
Quarter ended 30 Sep 2026: $4.7B, +5.3% on a year earlier; public on 7 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $189.6M, +2.7% on a year earlier; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $200.0M, -19% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $208.0M, -11% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $161.6M, -12% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $164.4M, -13% on a year earlier; public on 28 Feb 2023
Quarter ended 31 Mar 2023: $168.8M, -16% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $167.9M, -19% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $200.0M, +24% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $206.4M, +26% on a year earlier; public on 28 Feb 2024
Quarter ended 31 Mar 2024: $208.5M, +24% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $241.4M, +44% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $247.9M, +24% on a year earlier; public on 9 Nov 2024
Quarter ended 31 Dec 2024: $245.9M, +19% on a year earlier; public on 27 Feb 2025
Quarter ended 31 Mar 2025: $239.0M, +15% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $266.0M, +10% on a year earlier; public on 9 Aug 2025
Quarter ended 30 Sep 2025: $228.9M, -7.7% on a year earlier; public on 8 Nov 2025
Quarter ended 31 Dec 2025: $281.2M, +14% on a year earlier; public on 26 Feb 2026
Quarter ended 31 Mar 2026: $217.2M, -9.1% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $227.6M, -14% on a year earlier; public on 8 Aug 2026
Quarter ended 30 Sep 2026: $214.9M, -6.1% on a year earlier; public on 7 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 411; public on 14 Feb 2022
31 Mar 2022 report: 436; public on 16 May 2022
30 Jun 2022 report: 409; public on 15 Aug 2022
30 Sep 2022 report: 388; public on 14 Nov 2022
31 Dec 2022 report: 390; public on 14 Feb 2023
31 Mar 2023 report: 385; public on 15 May 2023
30 Jun 2023 report: 420; public on 14 Aug 2023
30 Sep 2023 report: 405; public on 14 Nov 2023
31 Dec 2023 report: 436; public on 14 Feb 2024
31 Mar 2024 report: 474; public on 15 May 2024
30 Jun 2024 report: 503; public on 14 Aug 2024
30 Sep 2024 report: 582; public on 14 Nov 2024
31 Dec 2024 report: 579; public on 14 Feb 2025
31 Mar 2025 report: 592; public on 15 May 2025
30 Jun 2025 report: 595; public on 14 Aug 2025
30 Sep 2025 report: 600; public on 14 Nov 2025
31 Dec 2025 report: 656; public on 17 Feb 2026
31 Mar 2026 report: 638; public on 15 May 2026
30 Jun 2026 report: 581; public on 14 Aug 2026
30 Sep 2026 report: 630; public on 16 Nov 2026
Federal obligations
Month from 1 Nov 2022: -$722 published
Month from 1 Dec 2022: $3.0M published
Month from 1 Jan 2023: $1.4M published
Month from 1 Feb 2023: $1.5M published
Month from 1 Mar 2023: $2.9M published
Month from 1 Apr 2023: $4.4M published
Month from 1 May 2023: $3.7M published
Month from 1 Jun 2023: $5.9M published
Month from 1 Jul 2023: $2.1M published
Month from 1 Aug 2023: $3.8M published
Month from 1 Sep 2023: $5.8M published
Month from 1 Oct 2023: $7.8M published
Month from 1 Dec 2023: $323K published
Month from 1 Jan 2024: -$1.5M published
Month from 1 Oct 2024: $314K published
Month from 1 Mar 2025: $541K published
Lobbying spend
Quarter from 1 Jan 2022: $20K published
Quarter from 1 Apr 2022: $20K published
Quarter from 1 Oct 2022: $20K published
Quarter from 1 Jan 2023: $20K published
Quarter from 1 Apr 2023: $20K published
Quarter from 1 Jul 2023: $20K published
Quarter from 1 Oct 2023: $20K published
Quarter from 1 Jan 2024: $20K published
Quarter from 1 Apr 2024: $20K published
Quarter from 1 Jul 2024: $20K published
Quarter from 1 Oct 2024: $20K published
Quarter from 1 Jan 2025: $20K published
Quarter from 1 Apr 2025: $20K published
Quarter from 1 Jul 2025: $20K published
Quarter from 1 Oct 2025: $20K published
Quarter from 1 Jan 2026: $20K published
Quarter from 1 Apr 2026: $20K published
Quarter from 1 Oct 2026: $20K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $128K (13 Mar 2026), 68% below its normal reading of $405K; higher than 13% of its own history.
Short interest spike: had 3.0M shares sold short in the 15 May 2026 report, 1.2× the same report last year Public on 28 May 2026.
Reported lobbying spend: $20K in Q3 2026, $20K in Q1 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
1 Jul 2026
New
Mr. Kyle Mulroyfor Valley Health System
Medicaid reform, physician financial arrangements, site neutral policiesHealth issues
Husch Blackwell, LLPfor Two Rivers Psychiatric Hospital, Inc.
Educated members of the Missouri congressional delegation on the status of the Two Rivers Psychiatric Hospital Medicare certification. Worked with the Missouri delegation on a response to the efforts of the Centers for Medicare and Medicaid to decertify Two Rivers involvement in the Medicare prograHealth issues
Husch Blackwell, LLPfor Two Rivers Psychiatric Hospital, Inc.
Educated members of the Missouri congressional delegation on the status of the Two Rivers Psychiatric Hospital Medicare certification. Worked with the Missouri delegation on a response to the efforts of the Centers for Medicare and Medicaid to decertify Two Rivers involvement in the Medicare prograHealth issues
had 3.0M shares sold short in the 29 May 2026 report, 1.4× the same report last year.
Same report last year: 2.1M; its normal report is 2.1M.
See the evidence
This period
3.0M (the 29 May 2026 report)
Normal report (median of 24 earlier)
2.1M
Typical spread (median absolute deviation)
93K
How far from its usual level
+4.4
Same report last year
2.1M
History used
3,073 days
the 29 May 2026 report24 earlier reportsnormal: 2.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.0M shares sold short in the 15 May 2026 report, 1.2× the same report last year.
Same report last year: 2.5M; its normal report is 2.1M.
See the evidence
This period
3.0M (the 15 May 2026 report)
Normal report (median of 24 earlier)
2.1M
Typical spread (median absolute deviation)
93K
How far from its usual level
+4.5
Same report last year
2.5M
History used
3,059 days
the 15 May 2026 report24 earlier reportsnormal: 2.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.7M shares sold short in the 31 Mar 2025 report, 1.8× the same report last year.
Same report last year: 1.5M; its normal report is 1.6M.
See the evidence
This period
2.7M (the 31 Mar 2025 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
192K
How far from its usual level
+3.8
Same report last year
1.5M
History used
2,649 days
the 31 Mar 2025 report24 earlier reportsnormal: 1.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.8M shares sold short in the 14 Mar 2025 report, 1.8× the same report last year.
Same report last year: 1.5M; its normal report is 1.5M.
See the evidence
This period
2.8M (the 14 Mar 2025 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
202K
How far from its usual level
+4.2
Same report last year
1.5M
History used
2,632 days
the 14 Mar 2025 report24 earlier reportsnormal: 1.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.5M shares sold short in the 15 May 2024 report, 1.5× the same report last year.
Same report last year: 1.7M; its normal report is 1.7M.
See the evidence
This period
2.5M (the 15 May 2024 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
141K
How far from its usual level
+4.0
Same report last year
1.7M
History used
2,329 days
the 15 May 2024 report24 earlier reportsnormal: 1.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
booked $7.8M in federal contract and grant obligations in September 2023, against none in the same month last year.
See the evidence
This period
$7.8M (September 2023)
Normal month (median of 5 earlier)
$0
Typical spread (median absolute deviation)
$0
How far from its usual level
+7.8
Same month last year
$0
History used
2,201 days
September 20235 earlier monthsnormal: $0
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
booked $5.8M in federal contract and grant obligations in August 2023, against none in the same month last year.
See the evidence
This period
$5.8M (August 2023)
Normal month (median of 5 earlier)
$0
Typical spread (median absolute deviation)
$0
How far from its usual level
+5.8
Same month last year
$0
History used
2,171 days
August 20235 earlier monthsnormal: $0
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
saw 71 13F filers open a new position in the quarter ended 30 Jun 2023, 1.4× the same quarter last year.
Same quarter last year: 52; its normal quarter is 45.5.
See the evidence
This period
71 (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
45.5
Typical spread (median absolute deviation)
4.5
How far from its usual level
+3.8
Same quarter last year
52
History used
3,560 days
the quarter ended 30 Jun 20238 earlier quartersnormal: 45.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
booked $5.7M in federal contract and grant obligations in May 2023, against none in the same month last year.
See the evidence
This period
$5.7M (May 2023)
Normal month (median of 5 earlier)
$0
Typical spread (median absolute deviation)
$0
How far from its usual level
+5.7
Same month last year
$0
History used
2,079 days
May 20235 earlier monthsnormal: $0
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
had 3.7M shares sold short in the 15 Jun 2022 report, 1.6× the same report last year.
Same report last year: 2.3M; its normal report is 2.1M.
See the evidence
This period
3.7M (the 15 Jun 2022 report)
Normal report (median of 24 earlier)
2.1M
Typical spread (median absolute deviation)
234K
How far from its usual level
+4.6
Same report last year
2.3M
History used
1,629 days
the 15 Jun 2022 report24 earlier reportsnormal: 2.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.6M shares sold short in the 31 May 2022 report, 1.9× the same report last year.
Same report last year: 1.9M; its normal report is 2.1M.
See the evidence
This period
3.6M (the 31 May 2022 report)
Normal report (median of 24 earlier)
2.1M
Typical spread (median absolute deviation)
234K
How far from its usual level
+4.3
Same report last year
1.9M
History used
1,614 days
the 31 May 2022 report24 earlier reportsnormal: 2.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.3M shares sold short in the 15 Jun 2021 report, 1.4× the same report last year.
Same report last year: 1.6M; its normal report is 1.4M.
See the evidence
This period
2.3M (the 15 Jun 2021 report)
Normal report (median of 24 earlier)
1.4M
Typical spread (median absolute deviation)
149K
How far from its usual level
+4.2
Same report last year
1.6M
History used
1,264 days
the 15 Jun 2021 report24 earlier reportsnormal: 1.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.4M shares sold short in the 14 May 2021 report, 1.1× the same report last year.
Same report last year: 2.2M; its normal report is 1.4M.
See the evidence
This period
2.4M (the 14 May 2021 report)
Normal report (median of 24 earlier)
1.4M
Typical spread (median absolute deviation)
149K
How far from its usual level
+4.4
Same report last year
2.2M
History used
1,232 days
the 14 May 2021 report24 earlier reportsnormal: 1.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.2M shares sold short in the 30 Apr 2021 report, 1.1× the same report last year.
Same report last year: 2.0M; its normal report is 1.4M.
See the evidence
This period
2.2M (the 30 Apr 2021 report)
Normal report (median of 24 earlier)
1.4M
Typical spread (median absolute deviation)
149K
How far from its usual level
+3.8
Same report last year
2.0M
History used
1,218 days
the 30 Apr 2021 report24 earlier reportsnormal: 1.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
drew 5,554 Wikipedia page views in the week of 28 Sep 2020, 8.1× the same week last year.
Same week last year: 682; its normal week is 536.
See the evidence
This period
5,554 (the week of 28 Sep 2020)
Normal week (median of 26 earlier)
536
Typical spread (median absolute deviation)
96
How far from its usual level
+25.1
Same week last year
682
History used
642 days
the week of 28 Sep 202026 earlier weeksnormal: 536
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
Showing the newest 40 of 70 entries; narrow the window or the kind of data to see older ones.
Not listed: 168 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0000352915
Ticker
UHS
Domain
uhs.com
Employer name
Aiken Professional Association, LLC, COLUMBUS HOSPITAL, Psychiatric Solutions, LLC, River Oaks, Inc. d/b/a River Oaks Hospital and 4 more (8 unverified)
Fein
20-5093162, 27-3493136, 52-1357729, 61-1850432 and 2 more (6 unverified)
Hq location
PA|KING OF PRUSSIA|19406 (1 unverified)
Lobbying client
two rivers psychiatric hospital, uhs of delaware, valley health system
Name
1001 Medical Park Drive LLC, 2012 W. University Properties, LLC, 2026 W. University Properties, LLC, ABS LINCS KY, LLC and 892 more
Uei
DDZ8GKV951M4
Wikidata
Q7893967
Wikipedia
Universal Health Services
DOL H-1B labor condition applications and PERM certifications24 data points19 Jan 2026 to 21 Sep 2026
Federal lobbying disclosures (LDA)13 records, 255 data points10 Apr 2002 to 30 Sep 2026
SEC Form 13F institutional holdings1 record, 481 data points30 Jun 2013 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)145 records25 Feb 2016 to 6 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)768 data points31 Dec 2007 to 30 Sep 2026
SEC Form 4 insider transactions52 records, 156 data points9 Mar 2016 to 13 Mar 2026
FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards316 data points20 Sep 2017 to 21 Feb 2025
WARN layoff notices (state labor agencies)1 record, 3 data points31 Mar 2008 to 1 Apr 2008
Wikipedia pageviews2881 data points1 Jan 2019 to 20 Nov 2026